BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson’s Drug
BofA Securities has upgraded Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines.
The company’s initial focus is on improving small molecule drug discovery and development in targeted oncology and genetically defined conditions.
The company has a pipeline of four preclinical candidates. In July, Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300 in hypochondroplasia (HCH), the most common form of dwarfism.
TYRA-300 increased the length of the appendicular skeleton in the FGFR3 mutated mice: the femur by 3.70% compared to the vehicle, the tibia by 3.75%, the humerus by 3.22%, and the ulna by 5.03%.
TYRA-300 also increased the size of the foramen magnum by 5.88% (p<0.05) in mice. TYRA-300 demonstrated binding against …
Full story available on Benzinga.com